1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Dementia Associated With Alzheimer%s Disease-Pipeline Insights, 2017


DelveInsight’s, “ Dementia Associated With Alzheimer's Disease-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Dementia Associated With Alzheimer's Disease. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Dementia Associated With Alzheimer's Disease. DelveInsight’s Report also assesses the Dementia Associated With Alzheimer's Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Dementia Associated With Alzheimer's Disease
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Dementia Associated With Alzheimer's Disease and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Dementia Associated With Alzheimer%s Disease-Pipeline Insights, 2017
Illustrative

- Dementia Associated With Alzheimer's Disease Overview
- Dementia Associated With Alzheimer's Disease Pipeline Therapeutics
- Dementia Associated With Alzheimer's Disease Therapeutics under Development by Companies
- Dementia Associated With Alzheimer's Disease Filed and Phase III Products
- Comparative Analysis
- Dementia Associated With Alzheimer's Disease Phase II Products
- Comparative Analysis
- Dementia Associated With Alzheimer's Disease Phase I and IND Filed Products
- Comparative Analysis
- Dementia Associated With Alzheimer's Disease Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Dementia Associated With Alzheimer's Disease - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Dementia Associated With Alzheimer's Disease - Discontinued Products
- Dementia Associated With Alzheimer's Disease - Dormant Products
- Companies Involved in Therapeutics Development for Dementia Associated With Alzheimer's Disease
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Dementia Associated With Alzheimer's Disease, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Dementia Associated With Alzheimer's Disease Assessment by Monotherapy Products
- Dementia Associated With Alzheimer's Disease Assessment by Combination Products
- Dementia Associated With Alzheimer's Disease Assessment by Route of Administration
- Dementia Associated With Alzheimer's Disease Assessment by Stage and Route of Administration
- Dementia Associated With Alzheimer's Disease Assessment by Molecule Type
- Dementia Associated With Alzheimer's Disease Assessment by Stage and Molecule Type
- Dementia Associated With Alzheimer's Disease Therapeutics - Discontinued Products
- Dementia Associated With Alzheimer's Disease Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Dementia Associated With Alzheimer's Disease, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Dementia Associated With Alzheimer's Disease Assessment by Monotherapy Products
- Dementia Associated With Alzheimer's Disease Assessment by Combination Products
- Dementia Associated With Alzheimer's Disease Assessment by Route of Administration
- Dementia Associated With Alzheimer's Disease Assessment by Stage and Route of Administration
- Dementia Associated With Alzheimer's Disease Assessment by Molecule Type
- Dementia Associated With Alzheimer's Disease Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Vascular Dementia Forecast in 13 Major Markets 2017-2027

Epiomic Epidemiology Series: Vascular Dementia Forecast in 13 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • January 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Vascular Dementia in 13 Major Markets Vascular Dementia (VaD) is the second most common form of dementia after Alzheimer disease. ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...

Alzheimer’s disease (AD) - Epidemiology Forecast To 2023

Alzheimer’s disease (AD) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Alzheimer’s disease (AD) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Alzheimer’s disease (AD) in seven major markets (US, France, Germany, ...

Cns Drug News 19 September 2016

September 2016 $ 1255

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.